A Prospective Study of Mid-Trimester MCP-1 Levels as a Predictor of Preterm Delivery

• Published in: Medicines (Basel, Switzerland) Vol. 10; no. 1; p. 7
• Main Authors: Bogavac, Mirjana A, Ćelić, Dejan D, Perić, Tamara M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30-12-2022; MDPI
• Subjects: Amniocentesis; Amniotic fluid; Angiogenesis; Cervix; Chemokines; Childbirth & labor; Cytokines; Embryos; Endometrium; Fetuses; Gestational age; Infections; Inflammation; MCP-1; Placenta; prediction markers; Pregnancy complications; Premature birth; Premature labor; preterm delivery; Ultrasonic imaging; Womens health; United States > US; prediction markers; MCP-1; preterm delivery
• ISSN: 2305-6320; 2305-6320
• DOI: 10.3390/medicines10010007

Background: The prevention of preterm delivery (PTD) represents one of the major topics in modern obstetrics. The aim was to design a prospective study and investigate if mid-trimester serum and amniotic fluid levels of MCP-1 could predict the occurence of spontaneous PTD. Methods: The study involved 198 women who underwent genetic amniocentesis and blood sampling in the middle of their trimester. After applying the criteria for inclusion in the study, there were 16 respondents in the study group, and 38 respondents in the control group. Level of MCP-1 in amniotic fluid and serum was measured with commercially available enzyme-linked immunosorbent assays (ELISA) and statistical analysis was conducted. Results: There was no statistically significant difference in serum or amniotic fluid MCP1 levels between PTD and the control groups. Conclusion: The results suggest that MCP-1 is probably not the most relevant marker for predicting PTD. This study provides new normative data for MCP-1 levels in amniotic fluid and maternal sera and is a valuable tool for future diagnostic and comparative studies.